CDMO Growth Leverage Akums’ strong CDMO revenue share (over 80% of total revenue in Q1 FY27) and expanding API manufacturing capabilities to propose end-to-end development and scalable manufacturing partnerships for global pharma companies seeking reliable, integrated CDMO services.

Diversified Capacity Target collaborations across multiple dosage forms and therapeutic areas, including oral solids, liquids, sterile injectables, hormones, personal care, ayurvedic, nutraceuticals, and animal health, to offer flexible manufacturing solutions for varied product pipelines.

Strategic Partnerships Capitalize on recent partnerships and interest from international players (for example Oriflame) to pitch co-development and local Indian production opportunities for global brands seeking cost-efficient, quality-compliant manufacturing in India.

Innovative Portfolio Position Akums as a source of innovative formulations such as the DCGI-approved H. pylori triple therapy combikit and seasonal skincare moisturization lines to identify white space products and regional launches for dermatology and infectious disease portfolios.

Financial Momentum Use strong Q4 FY26 and Q1 FY27 revenue growth signals, along with forecasted profitability stability, to engage finance teams with compelling business cases for scale-up manufacturing, capacity expansion, and long-term supply agreements.